Proteostasis Therapeutics Inc (NASDAQ:PTI) – Equities research analysts at Leerink Swann issued their Q1 2018 earnings estimates for Proteostasis Therapeutics in a note issued to investors on Tuesday. Leerink Swann analyst J. Schwartz anticipates that the company will post earnings of ($0.49) per share for the quarter. Leerink Swann also issued estimates for Proteostasis Therapeutics’ Q2 2018 earnings at ($0.48) EPS, Q3 2018 earnings at ($0.46) EPS, Q4 2018 earnings at ($0.47) EPS, FY2018 earnings at ($1.89) EPS, FY2019 earnings at ($1.52) EPS and FY2020 earnings at ($1.57) EPS.

Proteostasis Therapeutics (NASDAQ:PTI) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.16. The company had revenue of $1.55 million for the quarter, compared to the consensus estimate of $1.38 million. Proteostasis Therapeutics had a negative return on equity of 93.15% and a negative net margin of 712.49%.

A number of other analysts have also commented on the company. Robert W. Baird boosted their target price on Proteostasis Therapeutics from $13.00 to $25.00 and gave the company an “outperform” rating in a research report on Tuesday. Zacks Investment Research lowered Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 18th.

Shares of Proteostasis Therapeutics (NASDAQ PTI) traded down $0.67 during trading on Thursday, reaching $5.47. The company had a trading volume of 4,317,800 shares, compared to its average volume of 316,455. Proteostasis Therapeutics has a twelve month low of $1.41 and a twelve month high of $16.67.

A number of institutional investors have recently bought and sold shares of the stock. FMR LLC lifted its stake in Proteostasis Therapeutics by 2.3% in the second quarter. FMR LLC now owns 2,944,915 shares of the company’s stock valued at $13,782,000 after purchasing an additional 66,111 shares during the last quarter. Jennison Associates LLC lifted its stake in Proteostasis Therapeutics by 6.2% in the second quarter. Jennison Associates LLC now owns 2,075,439 shares of the company’s stock valued at $9,713,000 after purchasing an additional 120,575 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Proteostasis Therapeutics by 425.4% in the third quarter. JPMorgan Chase & Co. now owns 1,124,602 shares of the company’s stock valued at $2,361,000 after purchasing an additional 910,550 shares during the last quarter. Bain Capital Public Equity Management LLC purchased a new position in Proteostasis Therapeutics in the second quarter valued at approximately $1,233,000. Finally, Sabby Management LLC lifted its position in shares of Proteostasis Therapeutics by 109.6% during the second quarter. Sabby Management LLC now owns 125,151 shares of the company’s stock worth $586,000 after acquiring an additional 65,451 shares in the last quarter. Institutional investors and hedge funds own 68.08% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Proteostasis Therapeutics Inc Expected to Earn Q1 2018 Earnings of ($0.49) Per Share (PTI)” was published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/12/14/proteostasis-therapeutics-inc-expected-to-earn-q1-2018-earnings-of-0-49-per-share-pti.html.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Earnings History and Estimates for Proteostasis Therapeutics (NASDAQ:PTI)

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.